These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 21061842

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R, Lynch K, Juneja S.
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM.
    Blood; 2003 May 15; 101(10):3794-800. PubMed ID: 12560227
    [Abstract] [Full Text] [Related]

  • 28. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA.
    Clin Cancer Res; 2003 Jun 15; 9(6):2092-7. PubMed ID: 12796373
    [Abstract] [Full Text] [Related]

  • 29. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
    Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O.
    Cancer; 2010 Jun 01; 116(11):2665-72. PubMed ID: 20310049
    [Abstract] [Full Text] [Related]

  • 30. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
    Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL.
    Blood; 2002 Mar 15; 99(6):1928-37. PubMed ID: 11877262
    [Abstract] [Full Text] [Related]

  • 31. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M.
    J Assoc Physicians India; 2007 Feb 15; 55():103-7. PubMed ID: 17571738
    [Abstract] [Full Text] [Related]

  • 32. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 15; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 33. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS, Wang YY, Zhao YZ, Yi SH, Qian LS, Wang GR, Yu Z, Wang Y, Wang JX, Qiu LG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb 15; 18(1):208-12. PubMed ID: 20137149
    [Abstract] [Full Text] [Related]

  • 34. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 15; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 35. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
    Cervera E, Candelaria M, López-Navarro O, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L, Cortes J, Gordillo-Bastidas D, Dueñas-González A.
    Clin Lymphoma Myeloma Leuk; 2012 Jun 15; 12(3):207-12. PubMed ID: 22420986
    [Abstract] [Full Text] [Related]

  • 36. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ, Zhang S, Liu XL.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb 15; 16(1):217-21. PubMed ID: 18315935
    [Abstract] [Full Text] [Related]

  • 37. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
    Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G.
    Haematologica; 2010 Jun 15; 95(6):908-13. PubMed ID: 20145273
    [Abstract] [Full Text] [Related]

  • 38. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 39. Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
    Falchi L, Rege-Cambrin G, Fava C, Donti E, Luzi D, Giugliano E, Gubbiotti M, Schippa M, Liberati AM.
    Cancer Genet Cytogenet; 2010 Jun 01; 199(2):139-42. PubMed ID: 20471518
    [Abstract] [Full Text] [Related]

  • 40. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM.
    Leukemia; 2003 Mar 01; 17(3):481-7. PubMed ID: 12646934
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.